Celltrion Pharm Inc (068760) — Capital Reinvestment Ratio

Latest as of September 2025: 0.10x

Celltrion Pharm Inc (068760) has a Capital Reinvestment Ratio of 0.10x as of September 2025, meaning it reinvests 0% of its operating cash flow (₩23.44 Billion) in capital expenditures (₩2.27 Billion). See Celltrion Pharm Inc balance sheet independence to measure how much of total assets are equity-financed.

Capital Reinvestment Ratio

0.10x
Capex / Operating Cash Flow

Operating Cash Flow

₩23.44 Billion
KRW

Capital Expenditures

₩2.27 Billion
KRW

Data as of

Sep 2025
Most recent filing

Celltrion Pharm Inc Capital Reinvestment Ratio (2014–2024)

This chart tracks Celltrion Pharm Inc's Capital Reinvestment Ratio across 8 annual periods. Check Celltrion Pharm Inc total reinvestment intensity to assess the company's total reinvestment commitment from operating cash flow.

Annual Capital Reinvestment Ratio for Celltrion Pharm Inc (2014–2024)

Year-by-year Capital Reinvestment Ratio for Celltrion Pharm Inc from 2014 to 2024. For live market cap and broader valuation context, see 068760 company net worth.

Year Reinvestment Ratio Operating CF (KRW) Capital Expenditures YoY Change
2024 0.11x ₩56.59 Billion ₩5.98 Billion ▼ -86.6%
2023 0.79x ₩8.76 Billion ₩6.90 Billion ▲ +487.0%
2021 0.13x ₩93.15 Billion ₩12.50 Billion ▼ -88.4%
2020 1.16x ₩36.25 Billion ₩41.98 Billion ▲ +5.8%
2019 1.09x ₩27.85 Billion ₩30.49 Billion ▲ +117.4%
2018 0.50x ₩14.31 Billion ₩7.21 Billion ▼ -85.4%
2015 3.44x ₩13.36 Billion ₩45.97 Billion ▲ +127.8%
2014 1.51x ₩17.33 Billion ₩26.16 Billion
Capital Reinvestment Ratio = ABS(Capital Expenditures) / Operating Cash Flow